Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTUNASDAQ:DSGNNASDAQ:ENGNNASDAQ:PRLD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$10.33+2.3%$8.53$5.51▼$11.73$201.77MN/A48,059 shs46,719 shsDSGNDesign Therapeutics$3.81-1.6%$3.77$2.60▼$7.77$216.29M1.77186,686 shs184,751 shsENGNenGene$4.24-1.2%$4.07$2.65▼$13.00$216.15M-0.36132,554 shs45,475 shsPRLDPrelude Therapeutics$0.89-1.5%$0.80$0.61▼$6.80$50.04M1.3272,508 shs74,248 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics+2.28%-2.09%+14.78%+34.33%+1,032,999,900.00%DSGNDesign Therapeutics-1.55%+8.55%-6.39%-22.40%-8.41%ENGNenGene-1.17%+22.90%+6.27%-32.08%-67.93%PRLDPrelude Therapeutics-1.54%+0.34%+0.34%+1.76%-78.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ADSGNDesign Therapeutics0.5572 of 5 stars1.00.00.00.03.22.50.6ENGNenGene2.5698 of 5 stars3.53.00.00.01.92.50.6PRLDPrelude Therapeutics2.725 of 5 stars3.24.00.00.00.05.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 3.00Buy$20.5098.45% UpsideDSGNDesign Therapeutics 2.00Hold$4.004.99% UpsideENGNenGene 3.00Buy$23.29449.19% UpsidePRLDPrelude Therapeutics 2.33Hold$4.00351.37% UpsideCurrent Analyst Ratings BreakdownLatest PRLD, ACTU, DSGN, and ENGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025PRLDPrelude TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/29/2025ENGNenGeneJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$18.00 ➝ $18.004/29/2025PRLDPrelude TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$4.00 ➝ $4.004/22/2025ACTUActuate TherapeuticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$21.004/8/2025PRLDPrelude TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/17/2025ACTUActuate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.003/11/2025ENGNenGeneMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$37.00 ➝ $34.003/11/2025ENGNenGeneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/A$4.96 per shareN/AENGNenGeneN/AN/AN/AN/A$6.17 per shareN/APRLDPrelude Therapeutics$7M7.15N/AN/A$4.32 per share0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$24.75MN/A0.00∞N/AN/AN/AN/AN/ADSGNDesign Therapeutics-$66.86M-$0.99N/AN/AN/AN/A-18.01%-17.38%8/4/2025 (Estimated)ENGNenGene-$55.14M-$1.52N/AN/AN/AN/A-16.69%-14.27%6/10/2025 (Estimated)PRLDPrelude Therapeutics-$121.83M-$1.69N/AN/AN/AN/A-66.89%-55.59%8/11/2025 (Estimated)Latest PRLD, ACTU, DSGN, and ENGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/10/2025Q2 2025ENGNenGene-$0.4768N/AN/AN/AN/AN/A5/15/2025Q1 2025ACTUActuate Therapeutics-$0.26-$0.32-$0.06-$0.32N/AN/A5/14/2025Q1 2025DSGNDesign Therapeutics-$0.28-$0.31-$0.03-$0.31N/AN/A5/6/2025Q1 2025PRLDPrelude Therapeutics-$0.47-$0.42+$0.05-$0.42N/AN/A3/10/2025Q4 2024DSGNDesign Therapeutics-$0.28-$0.24+$0.04-$0.24N/AN/A3/10/2025Q4 2024PRLDPrelude Therapeutics-$0.49-$0.38+$0.11-$0.38N/A$4.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/AENGNenGene$1.5837.29%N/AN/A N/APRLDPrelude TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A1.681.68DSGNDesign TherapeuticsN/A34.6134.61ENGNenGene0.0816.8716.87PRLDPrelude TherapeuticsN/A7.047.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/ADSGNDesign Therapeutics56.64%ENGNenGene64.16%PRLDPrelude Therapeutics79.72%Insider OwnershipCompanyInsider OwnershipACTUActuate Therapeutics69.34%DSGNDesign Therapeutics31.20%ENGNenGene10.40%PRLDPrelude Therapeutics63.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1019.53 millionN/AN/ADSGNDesign Therapeutics4056.77 million38.96 millionOptionableENGNenGene3150.98 million38.16 millionN/APRLDPrelude Therapeutics12056.46 million20.47 millionOptionablePRLD, ACTU, DSGN, and ENGN HeadlinesRecent News About These CompaniesPathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drugMay 15, 2025 | fiercebiotech.comPrelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical ProgramsMay 10, 2025 | msn.comPrelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 6, 2025 | globenewswire.comPrelude Therapeutics to Host Fireside Chat at Citizens Life Sciences Conference 2025May 5, 2025 | msn.comBoxer Capital Management LLC Purchases New Position in Prelude Therapeutics Incorporated (NASDAQ:PRLD)May 4, 2025 | marketbeat.comRenaissance Technologies LLC Increases Holdings in Prelude Therapeutics Incorporated (NASDAQ:PRLD)May 4, 2025 | marketbeat.comJMP Securities Reaffirms "Market Outperform" Rating for Prelude Therapeutics (NASDAQ:PRLD)May 1, 2025 | marketbeat.comPrelude Therapeutics to Participate in Citizens Life Sciences ConferenceMay 1, 2025 | globenewswire.comPrelude Therapeutics (PRLD) Projected to Post Quarterly Earnings on TuesdayMay 1, 2025 | marketbeat.comPrelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer TherapiesApril 30, 2025 | msn.comPrelude Announces Presentations at 2025 AACR Annual MeetingApril 25, 2025 | globenewswire.comPrelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should KnowApril 10, 2025 | zacks.comPrelude Therapeutics Founder Acquires 28% More StockMarch 29, 2025 | finance.yahoo.comPrelude Therapeutics CEO buys $467K in common stockMarch 28, 2025 | markets.businessinsider.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) Insider Buys $69,000.00 in StockMarch 28, 2025 | insidertrades.comPrelude Therapeutics stock surges on insider buyingMarch 27, 2025 | investing.comPrelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Purchases 47,500 SharesMarch 15, 2025 | insidertrades.comPrelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline AdvancementsMarch 14, 2025 | msn.comAnalysts Are Bullish on Top Healthcare Stocks: Prelude Therapeutics (PRLD), Corbus Pharmaceuticals (CRBP)March 12, 2025 | markets.businessinsider.comBarclays Sticks to Their Sell Rating for Prelude Therapeutics (PRLD)March 12, 2025 | markets.businessinsider.comPrelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77)March 10, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongNVIDIA’s NVLink Fusion Ups the Ante for AI InfrastructureBy Thomas Hughes | May 19, 2025View NVIDIA’s NVLink Fusion Ups the Ante for AI InfrastructureRockwell Automation: Tailwinds From Onshoring U.S. ProductionBy Thomas Hughes | May 8, 2025View Rockwell Automation: Tailwinds From Onshoring U.S. ProductionCan Shopify Stock Make a Comeback After an Earnings Sell-Off?By Gabriel Osorio-Mazilli | May 12, 2025View Can Shopify Stock Make a Comeback After an Earnings Sell-Off?PRLD, ACTU, DSGN, and ENGN Company DescriptionsActuate Therapeutics NASDAQ:ACTU$10.31 +0.21 (+2.12%) As of 05/23/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Design Therapeutics NASDAQ:DSGN$3.81 -0.06 (-1.55%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.81 0.00 (0.00%) As of 05/23/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.enGene NASDAQ:ENGN$4.24 -0.05 (-1.17%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$4.25 +0.01 (+0.24%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.Prelude Therapeutics NASDAQ:PRLD$0.89 -0.01 (-1.54%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.89 +0.00 (+0.09%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
